News
RHHBY
48.52
+0.68%
0.33
FDA shift in drug study requirements sends trial runners lower
TipRanks · 1d ago
FDA to reduce number of trials required for drug approvals, STAT reports
TipRanks · 1d ago
OpenAI acquires startup Neptune to enhance training process: report
Seeking Alpha · 2d ago
Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond
Seeking Alpha · 2d ago
REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD
NASDAQ · 3d ago
Roche price target raised to CHF 290 from CHF 255 at Morgan Stanley
TipRanks · 3d ago
FDA top drugs official Pazdur retiring shortly after starting - report
Seeking Alpha · 3d ago
Roche price target raised to CHF 300 from CHF 290 at Berenberg
TipRanks · 3d ago
Top drug regulator Richard Pazdur preparing to exit FDA, STAT News reports
TipRanks · 3d ago
Vaccine committee considers changes to childhood schedule, NY Times reports
TipRanks · 3d ago
Roche receives FDA clearance with CLIA waiver for pertussis point-of-care test
TipRanks · 3d ago
Berenberg Bank Sticks to Its Hold Rating for Roche Holding (RHHBY)
TipRanks · 4d ago
Roche Receives FDA And CE Mark Approvals For Point Of Care Test Differentiating Multiple Bordetella Infections
Benzinga · 4d ago
Roche Holding AG Commits to Achieve Net Zero by 2045
Reuters · 4d ago
Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy
Benzinga · 4d ago
Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK
TipRanks · 4d ago
Will Korlym Continue to Drive Corcept's Top Line in 2026?
NASDAQ · 4d ago
Trump Trade: U.S. confirms agreement with U.K. on pharmaceutical pricing
TipRanks · 4d ago
Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?
TipRanks · 4d ago
US government confirms agreement in principle with UK on pharmaceutical pricing
TipRanks · 4d ago
More
Webull provides a variety of real-time RHHBY stock news. You can receive the latest news about Roche Hldg through multiple platforms. This information may help you make smarter investment decisions.
About RHHBY
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.